secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aclaris Therapeutics, Inc. (ACRS)
CIK:        0001557746
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0001558370-25-006851
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aclaris reports Q1 net loss $15.1M, cash runway extended to H1 2028; multiple pipeline milestones ahead
--------------------------------------------------------------------------------

- Q1 net loss $15.1M vs $16.9M YoY; revenue $1.5M vs $2.4M; cash $190.5M as of March 31, 2025.
- Cash runway extended through first half of 2028, fully funding preclinical and clinical plans.
- Bosakitug Phase 2 in atopic dermatitis to start Q2 2025; seeking partners for respiratory indications.
- ATI-2138 Phase 2a AD top line results expected June 2025; ATI-052 IND cleared, Phase 1 starting Q2 2025.
- Jesse W. Hall appointed CMO; Sun Pharma injunction lifted, offering potential non-dilutive financing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1557746/000155837025006851/0001558370-25-006851-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1557746/000155837025006851/acrs-20250508x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-006851

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer